• Publications
  • Influence
AJCC Cancer Staging Manual
Purposes and Principles of Cancer Staging and End-Results Reporting are explained. Expand
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer:
Dose density improves clinical outcomes significantly, despite the lower than expected number of events at this time, and Sequential chemotherapy is as effective as concurrent chemotherapy. Expand
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
Daily use of aspirin is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous coloreCTal cancer. Expand
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
The addition of four cycles of paclitaxel after the completion of a standard course of CA improves the disease-free and overall survival of patients with early breast cancer. Expand
Cetuximab in the treatment of colorectal cancer.
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North
A statistically significant survival advantage for patients who had tumors > or = 4 cm supports consideration of adjuvant paclitaxel/carboplatin for stage IB patients who have large tumors, and CALGB 9633 was underpowered to detect small but clinically meaningful improvements. Expand
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth
This PCO addresses the utility of KRAS gene mutation testing in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (MoAb) therapy with cetuximab or panitumumab with a systematic review of the relevant literature. Expand
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
It is suggested that screening for UGT1A1*28 polymorphism may identify patients with lower SN-38 glucuronidation rates and greater susceptibility to irinotecan induced gastrointestinal and bone marrow toxicity. Expand
Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.
The diagnosis of CIPN may present a diagnostic dilemma due to the large number of potential toxic etiologies and conditions, which may mimic some of the clinical features; the diagnosis must be approached with care in such patients. Expand
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.
The high costs associated with cancer care have created a difficult situation for patients and the oncologists who care for them and will require greater understanding of all the risks and benefits of various treatment options as well as the consequences of specific choices. Expand